CERTOLIZUMAB PEGOL

Certolizumab pegol is an anti‑TNF biologic for rheumatoid arthritis and Crohn’s disease. Side effects include infections, injection‑site reactions, and headache.

SKU: 1adef3b5758d Category: Tag:

Product Description


Mechanism of Action

Certolizumab pegol is a PEGylated Fab’ fragment that neutralises tumour necrosis factor‑alpha (TNF‑α). It lacks an Fc region, preventing complement activation or antibody‑dependent cellular cytotoxicity. By binding soluble and membrane‑bound TNF‑α, it inhibits downstream NF‑κB activation, cytokine release, endothelial adhesion‑molecule expression and inflammatory‑cell recruitment.

Benefits and Advantages

Used in TNF‑α signalling research, autoimmune‑disease modelling (RA, Crohn’s), cytokine‑network studies, PEG‑bioconjugation research, and Fab‑fragment pharmacokinetic optimisation. Valuable for understanding selective TNF neutralisation without Fc‑mediated effects.

Side Effects and Risks

Risks include immunosuppression, infection risk (TB reactivation), injection‑site reactions, malignancy risk (long‑term), and immune‑dysregulation. Handle as a biologically active monoclonal‑fragment therapeutic.

Datasheet


Molecular Formula

C6464H9988N1722O2026S42

Molecular Weight

90000.0 g/mol

CAS Number

428863-50-7

Storage Condition

Store in a cool, dry place; protected from light

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

Xaliproden; 135354-02-8; xaliprodene; xaliprodeno; V8QL94KNQO

IUPAC/Chemical Name

Monoclonal antibody Fab’ fragment conjugated to polyethylene glycol

InChl Key

Unavailable for large molecules

InChl Code

Unavailable for large molecules

References

PubChem; ChemBL; FDA substance registry;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download